Simvastatin prevents and reverses depigmentation in a mouse model of vitiligo.

PubWeight™: 1.03‹?› | Rank: Top 15%

🔗 View Article (PMC 4366328)

Published in J Invest Dermatol on December 18, 2014

Authors

Priti Agarwal1, Mehdi Rashighi1, Kingsley I Essien1, Jillian M Richmond1, Louise Randall2, Hamidreza Pazoki-Toroudi3, Christopher A Hunter4, John E Harris1

Author Affiliations

1: Division of Dermatology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts, USA.
2: Department of Medicine, The University of Melbourne, Melbourne, Victoria, Australia.
3: Department of Physiology, Iran University of Medical Sciences, Tehran, Iran.
4: Department of Pathobiology, University of Pennsylvania School of Veterinary Medicine, Philadelphia, Pennsylvania, USA.

Articles citing this

Understanding mechanisms of autoimmunity through translational research in vitiligo. Curr Opin Immunol (2016) 0.86

Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo. Ann Transl Med (2015) 0.81

Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo. Immunol Rev (2016) 0.80

Keratinocyte-Derived Chemokines Orchestrate T-Cell Positioning in the Epidermis during Vitiligo and May Serve as Biomarkers of Disease. J Invest Dermatol (2016) 0.79

Exosomes derived from atorvastatin-modified bone marrow dendritic cells ameliorate experimental autoimmune myasthenia gravis by up-regulated levels of IDO/Treg and partly dependent on FasL/Fas pathway. J Neuroinflammation (2016) 0.77

A double-blind, placebo-controlled, phase-II clinical trial to evaluate oral simvastatin as a treatment for vitiligo. J Am Acad Dermatol (2017) 0.76

Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr (2016) 0.76

Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin (2017) 0.75

Interactome analysis of gene expression profile reveals potential novel key transcriptional regulators of skin pathology in vitiligo. Genes Immun (2015) 0.75

The role of the Th1 chemokine CXCL10 in vitiligo. Ann Transl Med (2015) 0.75

Advances in Vitiligo: An Update on Medical and Surgical Treatments. J Clin Aesthet Dermatol (2017) 0.75

Vitiligo blood transcriptomics provides new insights into disease mechanisms and identifies potential novel therapeutic targets. BMC Genomics (2017) 0.75

Recent advances in understanding vitiligo. F1000Res (2016) 0.75

Articles cited by this

Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2003) 12.34

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08

Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. Cell (1996) 10.49

A road map for those who don't know JAK-STAT. Science (2002) 5.67

Stimulation of bone formation in vitro and in rodents by statins. Science (1999) 5.55

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24

HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest (2001) 4.11

Impaired response to interferon-alpha/beta and lethal viral disease in human STAT1 deficiency. Nat Genet (2003) 3.95

The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol (2006) 3.30

STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med (2011) 3.11

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol (2006) 2.70

High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med (1998) 2.58

Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science (2001) 2.52

A novel anti-inflammatory role for simvastatin in inflammatory arthritis. J Immunol (2003) 2.37

Feedback regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in livers of mice treated with mevinolin, a competitive inhibitor of the reductase. J Clin Invest (1980) 2.26

A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8⁺ T-cell accumulation in the skin. J Invest Dermatol (2012) 2.05

Vitiligo-inducing phenols activate the unfolded protein response in melanocytes resulting in upregulation of IL6 and IL8. J Invest Dermatol (2012) 2.02

Stat1-independent regulation of gene expression in response to IFN-gamma. Proc Natl Acad Sci U S A (2001) 1.96

Vitiligo: interplay between oxidative stress and immune system. Exp Dermatol (2013) 1.85

Novel STAT1 alleles in otherwise healthy patients with mycobacterial disease. PLoS Genet (2006) 1.74

Murine cutaneous mastocytosis and epidermal melanocytosis induced by keratinocyte expression of transgenic stem cell factor. J Exp Med (1998) 1.70

Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol (2011) 1.70

Human complete Stat-1 deficiency is associated with defective type I and II IFN responses in vitro but immunity to some low virulence viruses in vivo. J Immunol (2006) 1.69

Mutant HSP70 reverses autoimmune depigmentation in vitiligo. Sci Transl Med (2013) 1.66

Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol (2009) 1.56

CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med (2014) 1.50

Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? Exp Dermatol (2008) 1.39

Non-cardiovascular effects associated with statins. BMJ (2014) 1.24

Statin-induced immunomodulatory effects on human T cells in vivo. Atherosclerosis (2004) 1.19

Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol (2006) 1.17

Six decades of vitiligo genetics: genome-wide studies provide insights into autoimmune pathogenesis. J Invest Dermatol (2011) 1.15

Vitiligo, reactive oxygen species and T-cells. Clin Sci (Lond) (2011) 1.14

Treatment of generalized vitiligo with anti-TNF-α Agents. J Drugs Dermatol (2012) 1.08

The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol (2009) 1.07

Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res (2001) 1.06

Statins downregulate K6a promoter activity: a possible therapeutic avenue for pachyonychia congenita. J Invest Dermatol (2011) 1.04

Activation of the unfolded protein response in vitiligo: the missing link? J Invest Dermatol (2012) 1.03

Simvastatin modulates cytokine-mediated endothelial cell adhesion molecule induction: involvement of an inhibitory G protein. J Immunol (2000) 1.01

Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo. Lipids Health Dis (2004) 0.99

Oxidative stress and autoimmune skin disease. Eur J Dermatol (2013) 0.99

HSP70i is a critical component of the immune response leading to vitiligo. Pigment Cell Melanoma Res (2011) 0.97

Monobenzone-induced depigmentation: from enzymatic blockade to autoimmunity. Pigment Cell Melanoma Res (2011) 0.92

Worsening of vitiligo and onset of new psoriasiform dermatitis following treatment with infliximab. J Cutan Med Surg (2011) 0.90

Molecular mechanisms underlying the inhibition of IFN-γ-induced, STAT1-mediated gene transcription in human macrophages by simvastatin and agonists of PPARs and LXRs. J Cell Biochem (2011) 0.85

Effect of Biologic Agents on Non-PASI Outcomes in Moderate-to-Severe Plaque Psoriasis: Systematic Review and Meta-Analyses. Dermatol Ther (Heidelb) (2012) 0.81

Topical simvastatin: preclinical evidence for a treatment of skin inflammatory conditions. J Dermatol Sci (2006) 0.80

Failure of alefacept in the treatment of vitiligo. J Drugs Dermatol (2013) 0.80

The role of statins in cancer prevention and treatment. Oncology (Williston Park) (2005) 0.78

Articles by these authors

Neutrophils Self-Regulate Immune Complex-Mediated Cutaneous Inflammation through CXCL2. J Invest Dermatol (2016) 0.76